Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Insight Pharma Reports | Immunotherapies and Vaccines for Cancer and Infectious Diseases Report Overview

Immunotherapies and Vaccines for Cancer and Infectious Diseases Report Overview

Author: Lucy J. Sannes, PhD, MBA

The field of therapeutic vaccines and immunotherapies is rapidly emerging as a promising area. Use of passive immunotherapy (i.e., antibody) products, for prevention of infection or for treatment of many diseases, including cancer, is widespread. In addition, some nonspecific immunomodulators on the market are used to treat certain cancers.

However, there is considerable interest in the development of novel, active specific immunotherapies and therapeutic vaccines for cancer. No active specific immunotherapy products have yet reached the market in the United States, but we may be getting close. Progress is also being made in the development of therapeutic vaccines and immunotherapies for treatment of chronic infectious diseases.

Immunotherapies and Vaccines for Cancer and Infectious Diseases reviews current pharmacological options for 12 major cancers being targeted by companies developing cancer immunotherapies or vaccines. While a large number of drugs are available for these particular cancers, poor survival rates demonstrate there is a clear need for more effective treatments. We then include a discussion of currently available immunotherapies for chronic infections, and infectious disease vaccines that are on the market.

We consider strategies companies are using to develop cancer immunotherapies and vaccines, as well as different types of infectious disease vaccines, and highlight the R&D challenges for these sectors. A large number of smaller biopharmaceutical companies, and a more limited number of major pharmaceutical companies, are developing a wide range of different approaches to stimulate the immune system.

The many different product candidates that are in development for the 12 cancers targeted in this report are reviewed. In addition, we briefly touch upon the numerous vaccines and immunotherapies that are in development for other cancers.

In our section on infectious disease, we discuss novel prophylactic vaccines that are in development for prevention of a wide range of different diseases. We then focus on therapeutic vaccines and immunotherapies being developed for treatment of chronic infections.

Immunotherapies and Vaccines for Cancer and Infectious Diseases examines a number of business considerations and trends in the fields of infectious disease and cancer immunotherapies and vaccines. Interviews with nine experts in this area are provided, giving their perspectives on the progress being made, and the challenges and hurdles faced by researchers and companies working in this emerging field.

Length 390 pages Date published October 2008
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions